Skip to main content

Patient Support Line 1-800-282-7630, Monday – Friday: 9 AM – 5 PM ET

Monitoring KISQALI Treatment

Monitoring Your Treatment

Your doctor may conduct certain tests before and during your treatment with KISQALI to determine if it's the right option for you. These tests may include:

Heart Monitoring

  • Electrocardiogram (ECG or EKG): An electrocardiogram, also known as an ECG or EKG, is a test that shows changes in the electrical activity of the heart over time

Blood Tests

  • Electrolytes Panel: A blood test that measures the main electrolytes in the body—potassium, calcium, phosphorus, and magnesium—to check for an imbalance of the electrolytes or an acid–base imbalance

  • Complete Blood Count: A measure of the number of red blood cells, white blood cells, and platelets in the blood. A complete blood count (CBC) also measures the amount of hemoglobin (substance in the blood that carries oxygen) and the hematocrit (the amount of whole blood that is made up of red blood cells)

  • Liver Function Test: A liver function test (LFT) is a blood test to measure the blood levels of certain substances released by the liver. A high or low level of certain substances can be a sign of liver disease

At any time, your health care team may stop, decrease, or tell you to wait to begin your treatment with KISQALI. You should always take KISQALI exactly as your doctor tells you.

Important Safety Information

What is the most important information I should know about KISQALI ?

KISQALI may cause serious side effects, including:

Lung problems. KISQALI may cause severe or life-threatening inflammation of the lungs during treatment that may lead to death. Tell your health care provider right away if you have any new or...


KISQALI is a prescription medicine used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has gotten worse or has spread to other parts of the body (metastatic), in combination with:

  • an aromatase inhibitor as the first endocrine-based therapy; or...